Trial Profile
An investigational trial comparing the efficacy and safety of once weekly NNC0148-0287 C (insulin 287) versus once daily insulin glargine, both in combination with metformin, with or without DPP-4 inhibitors, in insulin naïve subjects with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin icodec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 02 Mar 2021 Results published in the Annals of Internal Medicine
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 22 Sep 2020 Results published in the New England Journal of Medicine